Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Triapina com quimioterapia e radioterapia no tratamento de pacientes com câncer cervical ou vaginal IB2-IVA

11 de novembro de 2026 atualizado por: National Cancer Institute (NCI)

Estudo de Biodisponibilidade de Aumento de Dose de Fase I de Triapina Oral em Combinação com Quimiorradiação Concorrente para Câncer Cervical Localmente Avançado (LACC) e Câncer Vaginal

This phase I trial studies the side effects and best dose of triapine when given with radiation therapy and cisplatin in treating patients with stage IB2-IVA cervical or vaginal cancer. Triapine may stop the growth of cancer cells by blocking an enzyme needed for cell growth. Cisplatin is a drug used in chemotherapy that kills cancer cells by damaging their deoxyribonucleic acid (DNA) and stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Adding triapine to standard treatment with cisplatin and radiation therapy may kill more cancer cells.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. To determine the maximum tolerable dose (MTD) and recommended phase II dose (RP2D) of oral triapine when used in combination with cisplatin plus radiation therapy.

II. To determine the oral bioavailability of triapine. III. To describe the pharmacokinetics (PK) of oral and intravenous triapine.

SECONDARY OBJECTIVES:

I. To determine whether the metabolic complete response (mCR) rate of oral triapine in combination with cisplatin chemoradiation using fludeoxyglucose F 18 (18F-FDG)-positron emission tomography (PET)/computed tomography (CT) at post-therapy (3-month) is at least 70%.

II. To determine clinical overall response rate, progression-free survival, and overall survival.

III. To determine the correlation of methemoglobin proportion (%) and triapine pharmacokinetic exposure.

EXPLORATORY OBJECTIVE:

I. To determine whether active human immunodeficiency virus (HIV) antiretroviral therapy impacts the antitumor activity of triapine.

OUTLINE: This is a dose-escalation study of triapine.

Patients undergo pelvic external beam radiation therapy (EBRT) or intensity modulated radiation therapy (IMRT) 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of low dose rate (LDR) brachytherapy in week 6 or 5 fractions of high dose rate (HDR) brachytherapy at week 4 or 5. Patients also receive triapine intravenously (IV) over 120 minutes on day 1 and orally (PO) on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo magnetic resonance imaging (MRI) and FDG-PET/CT during follow-up.

Tipo de estudo

Intervencional

Inscrição (Real)

21

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • University of Alabama at Birmingham Cancer Center
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Estados Unidos, 90033
        • Los Angeles General Medical Center
      • Pasadena, California, Estados Unidos, 91105
        • Keck Medical Center of USC Pasadena
    • Kansas
      • Fairway, Kansas, Estados Unidos, 66205
        • University of Kansas Clinical Research Center
      • Kansas City, Kansas, Estados Unidos, 66160
        • University of Kansas Cancer Center
      • Overland Park, Kansas, Estados Unidos, 66211
        • University of Kansas Hospital-Indian Creek Campus
      • Westwood, Kansas, Estados Unidos, 66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40536
        • University of Kentucky/Markey Cancer Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • University of Michigan Rogel Cancer Center
      • Detroit, Michigan, Estados Unidos, 48201
        • Wayne State University/Karmanos Cancer Institute
      • Farmington Hills, Michigan, Estados Unidos, 48334
        • Weisberg Cancer Treatment Center
    • New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Rutgers Cancer Institute of New Jersey
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • University of Oklahoma Health Sciences Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Hillman Cancer Center
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • University of Virginia Cancer Center
      • Richmond, Virginia, Estados Unidos, 23298
        • VCU Massey Comprehensive Cancer Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Fêmea

Descrição

Inclusion Criteria:

  • Patient has a new, untreated histologic diagnosis of stage IB2 (> 5 cm), II, IIIB, IIIC or IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix or stage II-IVA squamous, adenocarcinoma, or adenosquamous carcinoma of the vagina not amenable to curative surgical resection alone; the presence or absence of lymph node metastasis will be based on pre-therapy 18F-FDG PET/CT; the patient must be able to tolerate imaging requirements of an 18F-FDG PET/CT scan

  • Age >= 18 years old

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2

  • Life expectancy greater than 6 months

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

  • Platelets >= 100 x 10^9/L

  • Hemoglobin (Hgb) >= 10.0 g/dL (blood transfusions to reach this amount are allowed)

  • Serum creatinine =< 1.5 mg/dL to receive weekly cisplatin

    • If serum creatinine is between 1.5 and 1.9 mg/dL, patients are eligible for cisplatin if the estimated creatinine clearance (CCr) is > 30 ml/min (for the purpose of estimating the CCr, the formula of Cockcroft and Gault for females should be used)
  • Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (in patients with known Gilbert syndrome, a total bilirubin =< 3.0 x ULN, with direct bilirubin =< 1.5 x ULN)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN

  • Able to take oral medication

  • Not pregnant and not breastfeeding; the effects of triapine on the developing human fetus are unknown; for this reason as well as because heterocyclic carboxaldehydethiosemicarbazones and radiation are known to be teratogenic, women of child-bearing potential and men must agree to use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; patient must have documented negative urine pregnancy test must be resulted within 7 days before initiating protocol therapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine; these potential risks may also apply to other agents used in this study

  • For HIV and hepatitis B/C (HEPB/C):

    • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for the dose escalation portion of this trial; for those patients who are enrolled in the HIV positive (+) expansion cohort, they must be HIV infected and be on retroviral therapy with an undetectable viral load within 6 months of enrollment
    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured; for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Able to understand and willingness to sign a written informed consent document

Exclusion Criteria:

  • Patient has had a prior invasive malignancy diagnosed within the last three years (except [1] non-melanoma skin cancer or [2] prior in situ carcinoma of the cervix)
  • Patients are excluded if they have received prior pelvic radiotherapy for any reason that would contribute radiation dose that would exceed tolerance of normal tissues at the discretion of the treating physician
  • Patients receiving any other investigational agents
  • Patients with known glucose-6-phosphate dehydrogenase deficiency (G6PD) are excluded due to an inability to administer the antidote for methemoglobinemia, methylene blue; pre-registration testing for G6PD is at the investigator's discretion and is not required for study enrollment
  • Patients who are taking any medication associated with methemoglobinemia; medication must be discontinued and must have a washout period of 4 halflives or 4 weeks, whichever is shorter
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or cisplatin
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic congestive heart failure; unstable angina pectoris; cardiac arrhythmia; known inadequately controlled hypertension; significant pulmonary disease including dyspnea at rest, patients requiring supplemental oxygen, or poor pulmonary reserve; or psychiatric illness/social situations that would limit compliance with study requirements
  • Patients with uncontrolled diabetes mellitus (fasting blood glucose controlled by medication, =< 200 mg/dL allowed)
  • Patients who have had a hysterectomy or are planning to have an adjuvant hysterectomy following radiation as part of their cervical cancer treatment are ineligible
  • Patients scheduled to be treated with adjuvant consolidation chemotherapy at the conclusion of their standard chemoradiation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Treatment (triapine, chemoradiation)

Patients undergo pelvic EBRT or IMRT 5 days per week for 5 weeks (25 fractions) with a 3-day boost in week 6, and 1 or 2 applications of LDR brachytherapy in week 6 or 5 fractions of HDR brachytherapy at week 4 or 5. Patients also receive triapine IV over 120 minutes on day 1 and PO on days 2-5, 8-12, 15-19, 22-26, and 29-33 within 90 minutes after pelvic irradiation, and cisplatin IV over 60-120 minutes once weekly for 5 weeks (days 2, 9, 16, 23, and 30). Treatment continues in the absence of disease progression or unacceptable toxicity. Patients may receive a 6th cycle of cisplatin IV during the parametrial boost or any make-up radiation treatment in a sixth week of external beam radiotherapy. Patients undergo the collection of blood samples on study and undergo MRI and FDG-PET/CT during follow-up.

Given IV

Outros nomes:
  • CDDP
  • Cis-diaminodicloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatina
  • Platinol
  • Abiplatina
  • Blastolem
  • Briplatina
  • Cis-diamina-dicloroplatina
  • Cis-diaminodicloro Platina (II)
  • Cis-diaminodicloroplatina
  • Cis-dicloroamina Platina (II)
  • Dicloreto de diamina cisplatina
  • Cisplatina II
  • Dicloreto de diamina cisplatina II
  • Citoplatino
  • Citosina
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatina
  • Cloreto de Peyrone
  • Sal de Peyrone
  • Placis
  • Plastistil
  • Platina
  • Platiblastina
  • Platiblastina-S
  • Platinex
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Diaminodicloreto de platina
  • Platiran
  • Platistina
  • Platosina

Undergo MRI

Outros nomes:
  • Ressonância magnética
  • Varredura de imagem por ressonância magnética
  • Imagem Médica, Ressonância Magnética / Ressonância Magnética Nuclear
  • SENHOR
  • Exame de ressonância magnética
  • Imagem NMR
  • Ressonância Magnética Nuclear
  • Ressonância Magnética (MRI)
  • ressonância magnética
  • Ressonância magnética (procedimento)
  • Ressonâncias magnéticas
  • RM estrutural

Correlative studies

Undergo collection of blood samples

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Undergo IMRT

Outros nomes:
  • IMRT
  • RT Modulado de Intensidade
  • Radioterapia de Intensidade Modulada
  • Radiação, Radioterapia de Intensidade Modulada
  • Radioterapia de intensidade modulada (procedimento)

Undergo FDG-PET/CT

Outros nomes:
  • TC
  • GATO
  • Tomografia
  • Tomografia Axial Computadorizada
  • Tomografia computadorizada
  • tomografia
  • Tomografia axial computadorizada (procedimento)
  • Tomografia computadorizada (TC)
  • Diagnóstico Cat Scan
  • Tipo de serviço de varredura de gato diagnóstico

Undergo FDG-PET/CT

Outros nomes:
  • Imagem Médica, Tomografia por Emissão de Pósitrons
  • BICHO DE ESTIMAÇÃO
  • PET scan
  • Tomografia por emissão de pósitrons
  • PT
  • Tomografia por emissão de pósitrons (procedimento)

Undergo LDR brachytherapy

Outros nomes:
  • Braquiterapia, SOE
  • Radiação Interna
  • Braquiterapia por Radiação Interna
  • Radioterapia Interna
  • Braquiterapia de Radiação
  • Radiação, Interna

Undergo pelvic EBRT

Outros nomes:
  • EBRT
  • Radioterapia Definitiva
  • Radiação de Feixe Externo
  • Radioterapia de Feixe Externo
  • Feixe Externo RT
  • radiação externa
  • Radioterapia Externa
  • radiação de feixe externo
  • Radiação, Feixe Externo
  • Telerradioterapia
  • Teleterapia
  • Radiação de teleterapia
  • Radioterapia Externa (convencional)

Undergo FDG-PET/CT

Outros nomes:
  • 18FDG
  • FDG
  • fludesoxiglicose F 18
  • Fludesoxiglicose (18F)
  • Fluodesoxiglicose F18
  • Flúor-18 2-Fluoro-2-desoxi-D-Glucose
  • Fluorodesoxiglicose F18

Undergo HDR brachytherapy

Outros nomes:
  • Braquiterapia, Alta Dose
  • HDR
  • Braquiterapia de alta dose (procedimento)

Given IV and PO

Outros nomes:
  • 3-aminopiridina-2-carboxaldeído tiossemicarbazona
  • 3-AP
  • 3-Apct
  • OCX-0191
  • OCX-191
  • OCX191
  • PAN-811

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Meia-vida de eliminação (t 1/2)
Prazo: Até 24 horas após a administração
Até 24 horas após a administração
Maximum Tolerated Dose (MTD)
Prazo: Up to 5 weeks

The MTD was determined following a standard 3+3 design is as follows: Escalation at 0/3 DLTs, dose-reduction if >1/3 DLT, and expansion to 6 if 1/3 DLTs. DLT is defined as the severe toxicity event that leads to the termination of the treatment as defined in section 5.5. The highest dose level where <2/6 DLTs are observed will be declared MTD

Up to 5 weeks
Number of Patients Who Experienced a DLT
Prazo: Up to 5 weeks

Number of patients that experienced a DLT, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0. DLTs are defined as the following adverse events if considered at least "possibly related" to a component of the study therapy and which occur from the start of treatment until completion of EBRT, prior to initiation of brachytherapy (i.e. the first 5 weeks if no treatments are missed): Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 3 toxicity not resolved with maximal intervention to Grade 0-2 over 7 days (except alopecia and fatigue); Any nausea, vomiting, diarrhea and elevation of serum creatinine level Grade 4 toxicity; Any other non-hematologic toxicity ≥Grade 3; Any hematologic toxicity of ≥ Grade 4; Grade ≥3 dyspnea; Inability to deliver at least 20 of the scheduled 25 administrations of triapine at the planned dose, allowing for 2 weeks to make up missed radiation days.

Inability to deliver

Up to 5 weeks
Bioavailability of Triapine
Prazo: Up to 2 weeks

The oral bioavailability of the oral form of the triapine will be measured as a numeric value using mass spectrophotometry.

Up to 2 weeks
Cmax
Prazo: Up to 24 hours after dosing

Maximum concentration

Up to 24 hours after dosing
Tmax
Prazo: Up to 24 hours after dosing

Time to maximum concentration,

Up to 24 hours after dosing
AUC
Prazo: Up to 24 hours after dosing

Area Under the Concentration-Time Curve (AUC 0-last)

Up to 24 hours after dosing

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Fludeoxyglucose F18-Positron Emission Tomography Computed Tomography Metabolic Complete Response (mCR) Rate
Prazo: At 3 months post-treatment

The mCR rate at recommended phase 2 dose, defined as a metabolic complete response on PET/CT will be defined as greater than -66% reduction in tumor FDG uptake at sites of abnormal tumor FDG uptake noted on pre-treatment FDG-PET study (considering normal cardiac or liver blood pool).

At 3 months post-treatment
Clinical Overall Response Rate
Prazo: 3 months post-treatment

Clinical response at the recommended phase 2 dose per RECIST v1.1 Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.

3 months post-treatment
Progression Free Survival (PFS)
Prazo: Up to 4 years and 2 months from start of treatment

Median number of months that patients survive without disease progression from end of treatment. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Up to 4 years and 2 months from start of treatment
Overall Survival (OS)
Prazo: Up to 4 years and 2 months from start of treatment

Median number of months that patients remain alive after end of treatment.

Up to 4 years and 2 months from start of treatment

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Sarah E Taylor, University of Pittsburgh Cancer Institute LAO

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

18 de setembro de 2019

Conclusão Primária (Real)

4 de junho de 2023

Conclusão do estudo (Estimado)

29 de abril de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

3 de novembro de 2015

Enviado pela primeira vez que atendeu aos critérios de CQ

3 de novembro de 2015

Primeira postagem (Estimado)

4 de novembro de 2015

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de novembro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • NCI-2015-01907
  • NCI-2015-01907 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • HCC 15-157
  • UPCI 15-157
  • 15-157
  • 9892 (Outro identificador: CTEP)
  • UM1CA186690 (Concessão/Contrato do NIH dos EUA)
  • 9892 (Outro identificador: UPMC Hillman Cancer Center LAO)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever